Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SINTX Technologies, Inc. (NASDAQ: SINT) SEC filings, offering detailed insight into the company’s silicon nitride biomaterials business, capital structure, and governance. Filings are sourced in real time from the SEC’s EDGAR system and organized so investors can quickly locate key documents.
Through SINTX’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, readers can review narrative business descriptions, risk factors, financial statements, and management’s discussion of its advanced ceramics and medical device operations. These reports also describe the company’s focus on infection‑resistant silicon nitride devices, polymer composites, and antipathogenic fabric technologies, as well as its U.S.‑based manufacturing footprint and patent portfolio.
Current reports on Form 8‑K document material events such as FDA 510(k) submissions and clearances, asset purchase agreements, at‑the‑market offering arrangements, warrant inducement transactions, and other financing activities. For example, recent 8‑K filings describe an ATM Offering Agreement with H.C. Wainwright & Co., an inducement agreement related to warrant exercises, and an asset purchase agreement for foot and ankle implant assets.
The DEF 14A proxy statement provides information on board elections, auditor ratification, executive compensation proposals, and equity incentive plans, along with details about the annual meeting of stockholders. Together, these filings help investors understand SINTX’s governance structure and shareholder matters.
Stock Titan’s platform enhances these documents with AI‑powered summaries that highlight important sections, such as business updates, capital‑raising terms, and key risk disclosures, reducing the time needed to interpret lengthy filings. Users can also review Form 4 and related insider transaction filings to see how directors and officers transact in SINTX common stock over time.
By using this page, investors can efficiently navigate SINTX’s 10‑K, 10‑Q, 8‑K, proxy, and insider filings, while AI‑generated insights point to the sections most relevant to the company’s silicon nitride technology platform and financial condition.
SiNtx Technologies, Inc. disclosed an agreement allowing holders to exercise existing warrants and receive new common stock purchase warrants. The holders may exercise existing warrants to acquire shares at $3.32 per share, and the company will issue New Warrants to purchase up to 1,649,147 common shares at $4.79 per share. Holders also agreed to pay $0.125 per New Warrant as consideration. The company expects to receive aggregate gross proceeds of approximately $3.8 million from exercise of the existing warrants, before placement agent fees and other offering expenses. The filing includes forms for the inducement letter, New Warrant, placement agent warrants and related exhibits, and is signed by CEO Eric K. Olson.
Sintx Technologies reported a grant of 70,000 restricted stock units (RSUs) to Kevin Trask, the company’s Chief Financial Officer, on 09/04/2025. The RSUs were issued under the 2025 Equity Incentive Plan and represent the contingent right to receive one share per RSU upon vesting. Twenty percent of the award vested immediately, and the remainder vests at 20% every six months thereafter. After the grant, Mr. Trask beneficially owns 90,000 shares of common stock.
Kevin Trask, Chief Financial Officer of SiNtx Technologies, Inc. (SINT) filed an Initial Statement of Beneficial Ownership (Form 3) reporting direct ownership of 4,376 shares of common stock and 20,000 restricted stock units (RSUs). The RSUs were granted under the 2020 Equity Incentive Plan, with 25% immediately vested and the remainder vesting over three years. The filing is dated 09/04/2025 and was signed by Kevin Ontiveros by power of attorney.
Kevin Patrick Murphy reports beneficial ownership of 225,914 shares of Sintx Technologies, Inc., representing 8.2% of the outstanding common stock based on an outstanding share count of 2,758,865. The disclosed position consists of 138,957 shares of common stock and 86,957 warrants to purchase common stock, and the filer reports sole voting and sole dispositive power over the full amount. The filing states the securities were not acquired to change or influence control of the issuer. The statement is filed on behalf of an individual reporting person, Kevin Patrick Murphy, who identifies as a U.S. citizen.
Jay M. Moyes, a director of SiNtx Technologies, Inc. (SINT), reported a purchase of 3,000 shares of common stock on 08/26/2025 at a reported price of $3.5854 per share. Following the transaction, he beneficially owns 3,000 shares directly. The Form 4 was signed under power of attorney on 08/27/2025. No derivative transactions or additional holdings were reported.
Gregg R. Honigblum, a Director and Chief Investment Officer of SiNtx Technologies, Inc. (SINT), reported multiple open-market purchases on 08/26/2025. The Form 4 shows ten separate purchases of 5,000 shares each, bringing his total beneficial ownership to 64,000 shares. Purchase prices ranged from $3.60 to $3.75 per share. The filing was signed by an agent on 08/27/2025.
Eric K. Olson, President and CEO and a director of Sintx Technologies, Inc. (SINT), reported four open-market purchases on 08/22/2025. The filings show acquisitions of 3,500 shares at $3.37, 5,000 shares at $3.69, 775 shares at $3.64, and 1,200 shares at $3.67, for a total of 10,475 shares purchased that day. Following these transactions, Mr. Olson beneficially owned 24,975 shares. The Form 4 was signed by an authorized representative on 08/25/2025.
On 22 Jul 2025, SINTX Technologies (SINT) filed a Form 8-K (Item 7.01) to furnish a press release announcing it has submitted a 510(k) application to the U.S. Food & Drug Administration for silicon-nitride foot & ankle medical devices. The disclosure is informational only and is not deemed “filed” for liability purposes. No financial statements, revenue guidance, or cost estimates accompany the submission. While the filing marks a key regulatory milestone that could enable U.S. commercialization, the company did not provide an expected review timeline, market size, or projected financial impact.
FAQ
What is the current stock price of Sintx Technologies (SINT)?
What is the market cap of Sintx Technologies (SINT)?
